Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
Authors
Keywords
<sup>68</sup>Ga-DOTA-TOC, <sup>18</sup>F-FDG, PET/CT, NET, PRRT
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 43, Issue 9, Pages 1585-1592
Publisher
Springer Nature
Online
2016-02-27
DOI
10.1007/s00259-016-3328-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor
- (2014) Punit Sharma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT
- (2014) Sandip Basu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Contemporary nuclear medicine imaging of neuroendocrine tumours
- (2012) K.K. Wong et al. CLINICAL RADIOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
- (2012) Marianne Pavel et al. NEUROENDOCRINOLOGY
- Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study
- (2011) Niraj Naswa et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders
- (2011) Sandip Basu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A new dimension of FDG-PET interpretation: assessment of tumor biology
- (2011) Thomas C. Kwee et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
- (2010) T. Binderup et al. CLINICAL CANCER RESEARCH
- Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors
- (2009) Jonathan Strosberg et al. HUMAN PATHOLOGY
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
- (2009) D. Putzer et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
- (2009) M. Gabriel et al. JOURNAL OF NUCLEAR MEDICINE
- Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors
- (2009) E. Garin et al. JOURNAL OF NUCLEAR MEDICINE
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation
- (2009) Rudolf Arnold et al. NEUROENDOCRINOLOGY
- Functional imaging of neuroendocrine tumors with combined PET/CT using68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and18F-FDG
- (2008) Irfan Kayani et al. CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started